Janus Kinase Inhibitors: A Promising Therapeutic Option for Allergic Contact Dermatitis

Hadley Johnson; Jana Guenther; Brandon L Adler; JiaDe Yu

doi:10.12788/cutis.0705

Janus Kinase Inhibitors: A Promising Therapeutic Option for Allergic Contact Dermatitis

Cutis. 2023 Feb;111(2):92-105. doi: 10.12788/cutis.0705.

Authors

Hadley Johnson¹, Jana Guenther¹, Brandon L Adler¹, JiaDe Yu¹

Affiliation

¹ Ms. Johnson is from the University of Minnesota Medical School, Minneapolis. Ms. Guenther is from the Keck School of Medicine, University of Southern California, Los Angeles. Dr. Adler is from the Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles. Dr. Yu is from the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston.

PMID: 37075180
DOI: 10.12788/cutis.0705

Abstract

Janus kinase (JAK) inhibitors represent a promising class of small molecule inhibitors that treat a range of inflammatory skin diseases, such as atopic dermatitis (AD), psoriasis, and alopecia areata. Although the evidence for their use in allergic contact dermatitis (ACD) remains limited, early results from animal studies and case reports are promising. Herein, we provide an overview of JAK inhibitors and the evidence for their use in ACD.

MeSH terms

Dermatitis, Allergic Contact* / drug therapy
Dermatitis, Allergic Contact* / etiology
Humans
Janus Kinase Inhibitors* / therapeutic use
Janus Kinases / therapeutic use
Psoriasis* / drug therapy
Skin Diseases* / drug therapy

Substances

Janus Kinase Inhibitors
Janus Kinases